• Je něco špatně v tomto záznamu ?

Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools

Z. Nováková, CA. Foss, BT. Copeland, V. Morath, P. Baranová, B. Havlínová, A. Skerra, MG. Pomper, C. Barinka,

. 2017 ; 77 (7) : 749-764. [pub] 20170301

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031001

BACKGROUND: Prostate-specific membrane antigen (PSMA) is a validated target for the imaging and therapy of prostate cancer. Here, we report the detailed characterization of four novel murine monoclonal antibodies (mAbs) recognizing human PSMA as well as PSMA orthologs from different species. METHODS: Performance of purified mAbs was assayed using a comprehensive panel of in vitro experimental setups including Western blotting, immunofluorescence, immunohistochemistry, ELISA, flow cytometry, and surface-plasmon resonance. Furthermore, a mouse xenograft model of prostate cancer was used to compare the suitability of the mAbs for in vivo applications. RESULTS: All mAbs demonstrate high specificity for PSMA as documented by the lack of cross-reactivity to unrelated human proteins. The 3F11 and 1A11 mAbs bind linear epitopes spanning residues 226-243 and 271-288 of human PSMA, respectively. 3F11 is also suitable for the detection of PSMA orthologs from mouse, pig, dog, and rat in experimental setups where the denatured form of PSMA is used. 5D3 and 5B1 mAbs recognize distinct surface-exposed conformational epitopes and are useful for targeting PSMA in its native conformation. Most importantly, using a mouse xenograft model of prostate cancer we show that both the intact 5D3 and its Fab fragment are suitable for in vivo imaging. CONCLUSIONS: With apparent affinities of 0.14 and 1.2 nM as determined by ELISA and flow cytometry, respectively, 5D3 has approximately 10-fold higher affinity for PSMA than the clinically validated mAb J591 and, therefore, is a prime candidate for the development of next-generation theranostics to target PSMA. Prostate 77:749-764, 2017. © 2017 Wiley Periodicals, Inc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031001
003      
CZ-PrNML
005      
20171027103810.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.23311 $2 doi
035    __
$a (PubMed)28247415
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nováková, Zora $u Laboratory of Structural Biology, Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
245    10
$a Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools / $c Z. Nováková, CA. Foss, BT. Copeland, V. Morath, P. Baranová, B. Havlínová, A. Skerra, MG. Pomper, C. Barinka,
520    9_
$a BACKGROUND: Prostate-specific membrane antigen (PSMA) is a validated target for the imaging and therapy of prostate cancer. Here, we report the detailed characterization of four novel murine monoclonal antibodies (mAbs) recognizing human PSMA as well as PSMA orthologs from different species. METHODS: Performance of purified mAbs was assayed using a comprehensive panel of in vitro experimental setups including Western blotting, immunofluorescence, immunohistochemistry, ELISA, flow cytometry, and surface-plasmon resonance. Furthermore, a mouse xenograft model of prostate cancer was used to compare the suitability of the mAbs for in vivo applications. RESULTS: All mAbs demonstrate high specificity for PSMA as documented by the lack of cross-reactivity to unrelated human proteins. The 3F11 and 1A11 mAbs bind linear epitopes spanning residues 226-243 and 271-288 of human PSMA, respectively. 3F11 is also suitable for the detection of PSMA orthologs from mouse, pig, dog, and rat in experimental setups where the denatured form of PSMA is used. 5D3 and 5B1 mAbs recognize distinct surface-exposed conformational epitopes and are useful for targeting PSMA in its native conformation. Most importantly, using a mouse xenograft model of prostate cancer we show that both the intact 5D3 and its Fab fragment are suitable for in vivo imaging. CONCLUSIONS: With apparent affinities of 0.14 and 1.2 nM as determined by ELISA and flow cytometry, respectively, 5D3 has approximately 10-fold higher affinity for PSMA than the clinically validated mAb J591 and, therefore, is a prime candidate for the development of next-generation theranostics to target PSMA. Prostate 77:749-764, 2017. © 2017 Wiley Periodicals, Inc.
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $x imunologie $x farmakologie $7 D000911
650    _2
$a myší monoklonální protilátky $x imunologie $x farmakologie $7 D058846
650    12
$a antigeny povrchové $x imunologie $7 D000954
650    12
$a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $x imunologie $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    12
$a prostata $x imunologie $x patologie $7 D011467
650    12
$a nádory prostaty $x farmakoterapie $x imunologie $7 D011471
650    _2
$a teranostická nanomedicína $x metody $7 D000068936
650    _2
$a xenogenní modely - testy antitumorózní aktivity $x metody $7 D023041
655    _2
$a časopisecké články $7 D016428
700    1_
$a Foss, Catherine A $u The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.
700    1_
$a Copeland, Benjamin T $u The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.
700    1_
$a Morath, Volker $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, Freising-Weihenstephan, Germany.
700    1_
$a Baranová, Petra $u Laboratory of Structural Biology, Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
700    1_
$a Havlínová, Barbora $u Laboratory of Structural Biology, Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
700    1_
$a Skerra, Arne $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, Freising-Weihenstephan, Germany.
700    1_
$a Pomper, Martin G $u The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.
700    1_
$a Barinka, Cyril $u Laboratory of Structural Biology, Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 77, č. 7 (2017), s. 749-764
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28247415 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171027103855 $b ABA008
999    __
$a ok $b bmc $g 1254594 $s 992028
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 77 $c 7 $d 749-764 $e 20170301 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Možnosti archivace